Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Twenty questions about multiple sclerosis clinical trials methodologies.

W Pryse-Phillips1

  • 1Memorial University of Newfoundland, Health Sciences Centre, St. John's, Canada.

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|October 18, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ticlopidine aspirin stroke study: Outcome by vascular distribution of the qualifying event.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2015
Same author

An observational study of venoplasty in patients with multiple sclerosis.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2013
Same author

Genetic susceptibility to MS: a second stage analysis in Canadian MS families.

Neurogenetics·2001
Same author

The use of medications for cognitive enhancement.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2001
Same author

Pilot study to improve health outcomes for medication-induced headache sufferers.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·1999
Same author

Do we have drugs for dementia? No.

Archives of neurology·1999

Multiple sclerosis (MS) clinical trials face significant challenges in comparing results due to varied methods, endpoints, and outcome measures. These inconsistencies undermine confidence in therapeutic claims and highlight the need for methodological improvements in MS research.

Area of Science:

  • Neurology
  • Clinical Trials Methodology
  • Multiple Sclerosis Research

Background:

  • Heterogeneity in multiple sclerosis (MS) trial methodologies hinders comparative analysis and reduces confidence in therapeutic claims.
  • Variability in MS disease types, progression rates, and the inclusion of primary progressive MS complicate trial validity.
  • Current trial designs often lack standardization in endpoints, disease staging assessments, and definitions of treatment effects.

Purpose of the Study:

  • To critically evaluate the methodological limitations of recent multiple sclerosis (MS) clinical trials.
  • To identify factors contributing to the reduced validity and comparability of MS therapeutic trials.
  • To propose areas for improvement in the design and execution of future MS clinical trials.

Main Methods:

Related Experiment Videos

  • Analysis of methodological heterogeneity in MS clinical trials, including variations in disease classification, endpoints, and outcome measures.
  • Critique of the Expanded Disability Status Scale (EDSS) and proposed modifications for improved utility.
  • Examination of inclusion/exclusion criteria, dosing strategies, definitions of sustained worsening, and trial duration.
  • Evaluation of statistical paradigms like "intention to treat" and methods for assessing adverse events.
  • Assessment of the limitations of conventional Magnetic Resonance Imaging (MRI) in reflecting disease pathology and clinical outcomes.

Main Results:

  • Inconsistent methodologies, diverse endpoints (e.g., relapse rate, EDSS), and varied definitions of "sustained worsening" impair trial comparability.
  • The clinical significance of reduced relapse rates and the utility of current inclusion criteria are questioned.
  • Differences in drug dosing (body mass vs. surface area) and the statistical underpowering of trial extensions complicate interpretation.
  • Conventional MRI lacks sensitivity to key pathological changes like de/re-myelination and axonal loss, correlating poorly with clinical scores.
  • The "intention to treat" approach may reflect effectiveness rather than true efficacy, and the reporting of adverse events needs refinement.

Conclusions:

  • Recent multiple sclerosis (MS) therapeutic trials are subject to significant methodological criticisms.
  • Improvements in trial design, endpoint selection, outcome assessment, and MRI utilization are crucial for advancing MS therapeutics.
  • Standardization and refinement of methodologies are essential to increase the validity and comparability of MS clinical trial data.